Summary: From the editors of the Neurology Journal, Neurology Minute is a daily 1-2 minute brief podcast delivering a quick, practical rundown of what you need to know in neurology. Neurology Minute is hosted by Dr. Stacey Clardy, with contributions by leading neurologists and neuroscientists.
In the fifth part of an extended series with interviewer Dr. David Lapides, Dr. Jon Stone discusses differentiating FNDs and malingering symptoms in patients.
Dr. Aaron Rothstein discusses a paper in the Resident & Fellow section on hippocampal sclerosis in cerebral malaria.
Dr. Eoin Flanagan discusses anti-Ma2 paraneoplastic syndrome.
Dr. Kiran Thakur and Dr. Greer Waldrop give the main takeaways from their paper on the World Health Organization’s essential diagnostics list.
Dr. Sean Pittock discusses the main takeaways from his article on eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder.
Dr. David Lapides discusses depression in multiple sclerosis.
Dr. Aaron Rothstein discusses a less well-known imaging finding on a inflammatory subtype of cerebral amyloid angiopathy.
Dr. Eoin Flanagan discusses the cardinal sign in multiple sclerosis.
Dr. Emma Ciafaloni discusses the main takeaways from her paper combination therapy with nusinersen and AVXS-101 in SMA type 1.
Dr. Douglas Smith discusses the main takeaways from his paper, "Neuroimaging Findings in US Government Personnel With Possible Exposure to Directional Phenomena in Havana, Cuba" from JAMA.
In the first part of a multi-part series, Dan Xia talks about what he learns about neurologic care from his travels around the world, this time from Thailand.
Dr. David Lapides talks about Gaba A + B receptor encephalitis.
Dr. David Lapides discusses a Neurology: Neuroimmunology & Neuroinflammation review of IGG4 hypertrophic pachymeningitis from the July 2019 issue.
Dr. Mauricio Farez talks about the main points from his practice guidelines paper on vaccine-preventable infections and immunization in multiple sclerosis.
Dr. Steve Pearson gives more takeaways from the second part of his update discussion with Dr. Gordon Smith on drug pricing.